Gene therapy

#AAV #Gene therapy #Genetics / genomics #Genome sequencing #Recombinant DNA

DDW event focusses on rAAVs and long-read nanopore sequencing

Join DDW for this exclusive free event, ‘rAAV genome sequencing with Oxford Nanopore uncovers transgene integrity and packaging impurities’. The event will be supported by Oxford Nanopore Technologies. The event will feature experts Daniel Jachimowicz, Senior Bioscience Scientist at AstraZeneca BioPharmaceuticals R&D, Sweden,… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#News

#AAV #Gene therapy #Genetics / genomics #Genome sequencing #Recombinant DNA

rAAV Genome sequencing uncovers transgene integrity and packaging impurities

Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines. This webinar highlights how long-read nanopore sequencing as a comprehensive and sensitive QC method for rAAVs were evaluated — which is supporting internal research activities at AstraZeneca. You will hear how library preparation, assessed data quality,… Read More

Webinar date:
Supported by Oxford Nanopore Technologies
#Webinars

Cell and gene therapy
#FDA #Gene editing #Gene therapy #iECURE #In vivo #Paediatrics

FDA approves first in vivo gene insertion programme in infants

iECURE has been given the go-ahead to begin US trials of its investigational gene editing-based therapy in newborn males with neonatal onset Ornithine Transcarbamylase (OTC) deficiency. The Food and Drug Administration (FDA) Investigational New Drug (IND) clearance for ECUR-506 makes it the first in vivo gene… Read More

#Editor's Choice #News

#CAR-T #Cell and gene therapy #Cell therapy #Financing #Gene therapy

This week in drug discovery (18-22 March) 

News round-up for 18-22 March by DDW Digital Content Editor Diana Spencer. This has been an interesting week for cell and gene therapies, with two landmark FDA approvals, two significant fundraising efforts and potentially ground-breaking study results in glioblastoma. The top stories: ‘Dual-target’… Read More

#News

Gene therapy
#Cell and gene therapy #FDA #Gene therapy #Orchard Therapeutics #Paediatrics #Rare disease

First gene therapy for children with rare disease gets US sign-off

Lenmeldy (atidarsagene autotemcel) has become the first Food and Drug Administration (FDA)-approved gene therapy for the treatment of children with pre-symptomatic late infantile, pre-symptomatic early juvenile or early symptomatic early juvenile metachromatic leukodystrophy (MLD). Metachromatic leukodystrophy is a debilitating, rare genetic disease affecting the brain and nervous system. It is… Read More

#News #Regulatory #Trending News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Solid tumours

New DDW Highlights podcast: 26 February 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  In a breakthrough for advanced therapies, this week saw the FDA approve the first… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Solid tumours

This week in drug discovery (19-23 February) 

News round-up for 19-23 February by DDW Digital Content Editor Diana Spencer. In a breakthrough for advanced therapies, this week saw the FDA approve the first ever cell therapy for solid tumour cancers, but there were other significant developments in the cell and gene therapy space. The… Read More

#News

Tau proteins
#Alzheimer's #Gene therapy #Preclinical investigations #Tau protein #Voyager Therapeutics

New data validates tau silencing gene therapy for Alzheimer’s

Voyager Therapeutics has announced new data from its two preclinical programmes targeting pathological tau for the treatment of Alzheimer’s disease. Data on VY-TAU01, Voyager’s lead anti-tau antibody candidate, and on Voyager’s tau silencing gene therapy programme will be presented at the upcoming 2024 International Conference on Alzheimer’s and… Read More

#Editor's Choice #News

Drug discovery technology
#2024 predictions #Antibody drug conjugate (ADC) #Artificial intelligence (AI) #Gene therapy

Key drug development trends and predictions for 2024

Dr Julie Warner is Vice President of Regulatory Affairs at drug development consultancy, Boyds. In this article, she provides her expert insights into the key trends and developments expected to shape the global drug development industry this year. Financial landscape In 2023, life science companies experienced a significant decrease in… Read More

#Exclusive Content #Trends & Analysis

Cell and gene therapy
#Advanced Therapies #Cell and gene therapy #Drug discovery #Gene therapy #Webinar

Cell & gene therapies: How can market growth be sustained to maximise on opportunities?

In this on-demand webinar, hosted by DDW and sponsored by Astrea Bioseparations, learn about how market growth can be sustained to maximise on opportunities in cell and gene therapy (CGT). You will hear from Doug Danison, Head of Commercial Strategy and Operations for Bayer CGT, Mark Treherne, Commercial Research Scientist… Read More

Webinar date:
Sponsored by Astrea Bioseparations
#Webinars

Researchers in a lab
#Drug development #Gene therapy #iPSC #Preclinical development #Webinar

How iPSC derived cells can support drug and gene therapy development

DDW recently hosted a webinar ‘Discover how iPSC derived cells can be used to support the development of drug and gene therapies’, supported by DefiniGEN. The event outlined how iPSC derived cells can be used to advance the efficiency and efficacy of disease modelling and covered topics including functionality, modelling… Read More

#Exclusive Content

Adenovirus
#AAV #Cell and gene therapy #Gene delivery #Gene therapy #Roundtable

Guide to using AAV vectors in gene therapy

In 2023, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. The event aimed to help the audience understand the AAV workflow, from upstream methods for AAV production and validation to downstream analysis of the packaged product for… Read More

#Exclusive Content

Neuroscience
#Cerebrotendinous xanthomatosis #Funding #Gene therapy #Neurodegenerative disorders #Neuroscience #Vivet Therapeutics

Funds advance gene therapy for cerebrotendinous xanthomatosis 

Vivet Therapeutics has received €4.9 million from the French government to advance the development of a gene therapy for the treatment of cerebrotendinous xanthomatosis (CTX), a rare neurodegenerative disease.   This funding is from the “Innovations in biotherapies” framework of the France Health Innovation Plan 2030 and specifically the acceleration strategy… Read More

#Business & Investment #News

Child with hearing aids
#Akouos #Eli Lilly #Gene mutation #Gene therapy #Hearing Loss #Phase II trial

Gene therapy cures genetic hearing loss

In the first case of its kind, gene therapy has restored hearing in a patient in the United States. Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 Phase I/II study participant. AK-OTOF is a gene… Read More

#News #Trending News

#Gene therapy #Kyowa Kirin #Mergers and acquisitions #Orchard Therapeutics

Kyowa Kirin completes acquisition of Orchard Therapeutics

Japan-based pharma company Kyowa Kirin has successfully completed the acquisition of gene therapy developer Orchard Therapeutics. Orchard Therapeutics’ portfolio comprises Libmeldy (atidarsagene autotemcel), which is intended for the treatment of eligible patients with early-onset metachromatic leukodystrophy (MLD), a rare and life-threatening inherited disease of the body’s metabolic system. Libmeldy is… Read More

#Business & Investment #News

Heart
#Asklepios BioPharmaceutical #Cardiovascular disease #Gene therapy #Heart failure #Phase II trial

One-time gene therapy for heart failure moves to Phase II trial

Gene therapy company Asklepios BioPharmaceutical (AskBio, a subsidiary of Bayer) has announced plans to initiate a Phase II trial of gene therapy AB-1002 for the treatment of congestive heart failure (CHF). GenePHIT (Gene PHosphatase Inhibition Therapy) will evaluate the safety and efficacy of a single intracoronary… Read More

#News